SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as volume shipments of its NVIDIA Blackwell Ultra solutions begin, fueling discussions about earnings potential and a possible stock re-rating. The community is weighing the significance of this catalyst against concerns regarding the company's past compliance issues. Bullish sentiment is strong, with many seeing SMCI as undervalued within the AI infrastructure landscape.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The stock is trending amid community discussion surrounding the fatal shooting of Charlie Kirk, a conservative activist, with community members offering diverse perspectives and theories. Some users are using the event to launch political attacks, while others are sharing news updates and expressing concerns about societal divisions. Additionally, the release of the Epstein files is a recurring theme in the conversation.

$VIX. The volatility index of the SPX.  The volatility of the SPX compressed, distilled, and put on the blockchain. That's the VIX777. Each token is meticulously and mathematically designed to profit from variation. At the VIX, utility IS volatility.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced,   VIX777 is a memecoin. It is completely useless and fulfills no purpose or utility. Partaking in the community in any way has no expectation of profit and is done for entertainment purposes only.

VIXCO

VIXCO ($VIX.X) is trending as traders discuss potential bullish momentum and a possible breakout, with some pointing to chart patterns and increased buying activity. Community members highlight the potential for a significant upward move, noting that big players and smart money may be positioning themselves in the crypto. Some traders believe the market is underestimating the potential of VIXCO.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as investors discuss the company's AI strategy and recent financial performance, including raised guidance. Community members are weighing the potential impact of AI on Adobe's growth and debating whether the stock's valuation reflects its future prospects, while considering analyst ratings and price targets.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid reports that Paramount Skydance is preparing a takeover bid, potentially setting off a bidding war with tech giants. Community chatter revolves around speculation of a buyout price, potential impact on streaming rivals like Netflix, and possible regulatory hurdles. The potential merger would unite major Hollywood studios and streaming services, HBO Max and Paramount+.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to increasing institutional backing and upcoming earnings, sparking optimism about the company's potential. The community is actively discussing the CEO's confidence, the undervaluation of the stock compared to its peers, and the possibility of a short squeeze. Investors are also noting the company's strategic partnerships and the potential impact of its AI-powered commerce solutions in the retail sector.

Wearable Devices Ltd. engages in the development of a non-invasive neural input technology that allows operation and control of digital devices using subtle finger movements and fingertip pressure. It offers Mudra band, a neutral input wristband. The company was founded by Asher Dahan, Guy Wagner, and Leeor Langer in March 2014 and is headquartered in Yokne'am Illit, Israel.

Wearable Devices Ltd

Wearable Devices (WLDS) is trending due to a recent $4 million direct offering, sparking discussions about its potential impact on the stock's price. While some community members express concerns about dilution, others view the offering as a sign of institutional confidence, highlighting the company's patents and potential for acquisition in the wearable tech space. The stock's volatile price action and low float continue to fuel speculative interest.

BGSF, Inc. engages in providing consulting, managed services, and professional workforce solutions. It operates through the Property Management and Professional segments. The Property Management segment offers office and maintenance talent in 38 states and D.C. to property management companies responsible for the apartment communities’ and commercial buildings’ day-to-day operations. The Professional segment is involved with specialized talent and business consultants for information technology, managed services, finance, accounting, legal and human resource. The company was founded on August 27, 2007, and is headquartered in Plano, TX.

BGSF Inc

BGSF is trending due to a special dividend announcement of $2 per share, sparking excitement among investors. Community members highlight the stock's low float and significant institutional ownership, suggesting potential for a substantial price increase. Some are comparing it to similar situations with other dividend stocks.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics (GALT) is trending due to increased community interest and speculation around potential catalysts, such as a buyout or partnership, following positive data for its drug Belapectin. The community is actively discussing the company's financial backing, key personnel, and the potential for a short squeeze given high short interest. Bullish sentiment is building around GALT's prospects in treating liver diseases and the possibility of FDA approval.

Upexi, Inc. engages in the development, manufacturing, and distribution of consumer products through direct-to-consumer network, wholesale partnerships, and major third-party platforms like Amazon. Its brands include LuckyTail, Prax, Cure Mushrooms, Moonwlkr, and Gumi Labs. The company was founded on September 5, 2018 and is headquartered in Tampa, FL.

Upexi Inc

UPXI is trending due to the addition of Arthur Hayes, co-founder of BitMEX, to their advisory committee, signaling a deeper move into DeFi and Solana ($SOL.X) ecosystem plays. The community is discussing the potential for partnerships and capital raises following the announcement, given the company's strategy of accumulating locked SOL tokens at a discount and earning yields.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (Fulcrum or the Company) (NASDAQ: FULC). Investors who...

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! FULC INVESTOR ALERT: Bronstein...

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) plunged 61.1% on Sept.
read more...

Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views

Latest Ratings for FULC
 DateFirmActionFromTo Mar 2022OppenheimerInitiates Coverage OnOutperform Aug 2021HC Wainwright & Co.MaintainsBuy Aug 2021SVB LeerinkMaintainsOutperform
 View More Analyst...

Shares of Fulcrum Therapeutics, Inc. (FULC) plummeted nearly 70% on Thursday, making it the biggest loser across U.S. exchanges, after the company announced the failure of its drug candidate aimed at treating a rare muscle disorder .The Phase 3 REACH trial for losmapimod, an experimental drug aimed at treating facioscapulohumeral muscular dystrophy (FSHD), did not meet its primary or secondary endpoints.FSHD, a rare genetic disorder that causes muscle weakness and wasting, reportedly affects about four in 100,000 individuals.Losmapimod was positioned to become the first approved therapy for this progressive muscle-wasting condition, but the trial’s failure marks a significant setback for Fulcrum and its ambitions.The trial’s failure is a particularly harsh blow given Sanofi’s recent $80 million bet on losmapimod just four months ago. The licensing deal carried hopes that late-stage success could propel the p38 inhibitor into a first-of-its-kind treatment for FSHD.Sanofi’s U.S.-listed shares were down 1.3% on the Nasdaq following the news.With $273.8 million in cash and equivalents, Fulcrum plans to shift focus to its remaining pipeline, led by pociredir, a Phase 1-stage drug for sickle cell disease that aims to increase fetal hemoglobin expression.However, the outlook remains bleak as analysts slashed their ratings and price targets on the stock.Stifel downgraded Fulcrum to ‘Hold’ from ‘Buy’, cutting its price target to $3 from $22, citing the “logical” but “disappointing” decision to discontinue losmapimod development.BofA dropped its rating to ‘Underperform’ from ‘Neutral’ and reduced its price target to $2 from $10.Leerink downgraded the stock to ‘Market Perform’ from ‘Outperform’ with a price target of $4, down from $16, pointing to high stakes and a lack of approved therapies for FSHD.Retail sentiment on Stocktwits turned sharply negative, to ‘extremely bearish’ (17/100), accompanied by increased message volume.<figure class="image"><a href="https://stocktwits.com/symbol/FULC"><img style="aspect-ratio:1314/308;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FULC_retail_sentiment_and_message_volume_scores_Sep_12_11b09f649a.png" alt="FULC retail sentiment and message volume scores Sep 12.png" width="1314" height="308"></a><figcaption>FULC retail sentiment and message volume scores Sep 12</figcaption></figure>One user lamented, “$FULC biggest risky play in a long time turned into my biggest loss in a long time. Sorry folks.”<stembedurl>https://stocktwits.com/RonIsWrong/message/585814681</stembedurl>Another bearish watcher predicted further declines, stating, “$FULC they have nothing else in the pipeline, going to 1.”<stembedurl>https://stocktwits.com/petoss/message/585822022</stembedurl>FULC stock has lost more than half of its value this year.Read next: <a href="https://stocktwits.com/news/markets/equity/berkshire-stock-falls-after-ajit-jain-slashes-stake/c7zxwMbR5T">Berkshire Hathaway Shares Dip After Insurance Chief Ajit Jain Slashes Stake In Firm By Over 50%: Retail Holds Strong</a>

Top Wall Street Loser Fulcrum Therapeutics Drags Retail Sentiment To Ground After Drug Trial Fails, Analysts Slash Ratings

Losmapimod was positioned to become the first approved therapy for a rare muscle-wasting condition, but the trial’s failure marks a significant setback for Fulcrum and its ambitions.

Equity

FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. (Fulcrum or the Company) (NASDAQ...

Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial

Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The company consider suspending the program.
read more...

Futures Gain As Post-Nvidia Tech Rally Goes Global, ECB Cuts

Futures Gain As Post-Nvidia Tech Rally Goes Global, ECB Cuts

 Futures are trading higher ahead of today's PPI report, extending on yesterday's post-NVDA rebound momentum, as a rally that...

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

FULC
Fulcrum Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FULC News

FULC Fulcrum Therapeutics Inc